Thirteen Chinese Innovative Biopharma Companies Secure New Funding Rounds

Mar 31, 2024 08:52 CST Updated 08:52

Proviva Therapeutics

Developer of Next-Generation Cytokine Anti-Tumor Immunotherapy

▎WuXi AppTec Content Team Report

Public information shows that as of March 30, at least 13 Chinese innovative drug research and development companies announced financing progress in March. Analyzing the financing information and product pipelines of these companies, we found the following characteristics:

In terms of financing rounds, the number of early-stage financings (before Series B)Account forBy approximately 69%；
In terms of the amount of financing, there is5 companiesThe company's financing amount exceeded 100 million RMB, includingShanghai Guangsheng Pharmaceutical Co., Ltd.Proviva Therapeutics,Proviva Therapeutics,NuriLite Healthcare,Huanuotai；
In terms of drug types, the products developed by these companies involvePhotodynamic Therapy,CAR-NK Therapy,Dual CAR-T Cell Therapy,Oncolytic Virus Therapy, Radiation Therapy, Live Biotherapeutics, Tumor VaccinesTypes such as.

The following is based on publicly available information sharing these 13HomeBasic Information of Emerging Companies: Explore Which Patients Their Innovative Therapies Are Expected to Benefit in the Future（This article only counts the events of companies announcing financing through official press releases. If there are any omissions, please feel free to supplement.）。ScanBelowQR code to access the PDF file of "Review of Global Financing Events over $50 Million in March 2024."

Shanghai Guangsheng Pharmaceutical Co., Ltd.

Established: 2018

Financing Round: Series A

News on March 1: Shanghai Guangsheng Pharmaceutical Co., Ltd. announced successCompleted A Round Financing of Over 100 Million RMB, This round is led byOriental FortuneExclusive Investment.Shanghai Guangsheng Pharmaceutical Co., Ltd. was founded in 2018,Committed toPromote the Development of Excitation Therapies such as Photodynamic and Sonodynamic Therapy，Mainly focusing on innovative photosensitizers and their related products. The company's CEO(CEO) isMs. Song Qingting

Currently,The first product of Shanghai Guangsheng Pharmaceutical Co., Ltd.——The anti-tumor photosensitizer "Sodium Chlorophyllin for Injection" is under clinical treatment.Phase 3 Registrational Clinical Study of Advanced Esophageal Cancer Expected to File for Market Approval in China This Year. In addition,Shanghai Guangsheng Pharmaceutical Co., Ltd. will continue to promote the innovative research and development of photo/acoustic dynamic therapy in the fields of esophageal cancer, colorectal cancer, glioma, high-grade squamous intraepithelial lesions, and other non-tumor indications.

Recommended Reading:Exclusive Interview with CEO Qingting Song of Shanghai Guangsheng Pharmaceutical Co., Ltd.

Kerun Biologic

Establishment Time:2005Year

Financing Round:A+Round

News on March 5: Kerun Biotech Completes Tens of Millions of Yuan in A+ Round Financing; This Round of Financing Led byZhirui InvestmentLead investment.Kerun Biologics was founded in 2005, focusing on the development of recombinant protein drugs. The founder of the company isDr. Shugang LiThe company's product pipeline focuses on the research and development of biologic macromolecular drugs in the fields of ophthalmology and oncology.

InOphthalmology Field，Kerun BiologicThe product pipeline covers retinal vascular diseases of the fundus, as well as dry eye, keratitis, and non-infectious uveitis of the ocular surface.In the field of anti-tumor, Kerun Biologic has developed a Class 1 new drugFor InjectionRecombinant carboxypeptidase G2, and is developing antibody-drug conjugates (ADC) for the treatment of hematological tumors such as leukemia and lymphoma.

Proviva Therapeutics

Date of Establishment:2019Year

Financing Round:AWheel

On March 5, Proviva Therapeutics announced the completion of a $18 million Series A financing round, led byLongpan Investment, Enran Venture CapitalAndXiantong CapitalJoint Investment.Proviva Therapeutics was founded in 2019 and is committed to developingNew Generation Cytokine Anti-Tumor Immunotherapy. The companyFounder and CEO isDr. Hongxing Zhou。

Currently,Proviva TherapeuticsBiological hasDevelopment了Next-Generation Immunocyte-Targeted Interleukin-2 (IL-2) Prodrug Fusion ProteinPTX-912. It is reported that,PTX-912 utilizesProviva TherapeuticsProdrug technology,Enables the IL-2 prodrug to be specifically activated in the tumor microenvironment, while targeting the activated IL-2 to tumor-specific effector T-cell subsets., to fully leverage the immune-activating and anti-tumor effects of IL-2 while enhancing safety. Currently, the drug has entered Phase 1 clinical trials in the United States.

ProBio Therapeutics

Established: 2019

Financing Round:A+Wheel

News on March 11: Proviva Therapeutics announced the completion of a 200 million RMB A+ round of financing. This round of financing was led byYou Mountain CapitalLeading investment,Yuanhe Origin, Pudao Capital, Guochuang QinzhìFollow-up Investment.Proviva Therapeutics was founded in 2019, focusing on the development of innovative immunocyte therapies. The company's CEO is Dr. Cao Zhuoxiao.

ProBio TherapeuticsThe FirstCAR-NK Product PipelineSNC103 has already achieved positive results in the investigator-initiated clinical research (IIT) phase, andApproved for clinical trials in China this February, intended for development as a treatmentModerate to Severe Refractory Systemic Lupus Erythematosus. The companyAnother R&DCarrying Two CAR MoleculesTheDual CAR-T Cell TherapySNC109 has also been approved for clinical trials in China and granted by the U.S. FDAOrphan Drug Designation, used for treatmentMalignant Glioma。

Yinghui Medicine

Established: 2020

Financing Round: A1 Round

News on March 11: Yinghui Medicine successfully completed its Series A1 round of financing worth tens of millions of RMB. This equity financing was exclusively invested by Shengyuan Zhiben. Established in 2020, Yinghui Medicine focuses on the development of oncolytic virus therapies. The founder of the company is Professor Huang Yinghui, who has over 20 years of research experience in the field of oncolytic viruses. Yinghui Medicine currently has five products, with the most advanced product, YH01, in Phase 1 clinical trials for the proposed indication of triple-negative breast cancer.

Xinyue Biotech

Established: 2021

Financing Round: Series A

On March 12, Xinyue Biotech announced the completion of a multi-million RMB A-round financing, which was invested by the company's original shareholder, Hecheng Capital. Xinyue Biotech, established in April 2021, focuses on the development of small-molecule innovative drugs, with Mr. He Xun serving as the chairman of the board. In just over two years since its establishment, the company has developed dozens of R&D pipelines and obtained four clinical trial approvals for both China and the US.

Nurelit Healthcare

Established: 2016

Financing Round: Series C

News on March 14, Neurite Medical announced the completionOver 300 Million Yuan in Series C Financing.This round of financing was invested by Chengdu Kechuang Investment, Chengdu BioCity Fund, Sichuan Venture Capital, etc., with existing shareholders such as Huaxing Kangping, Xinjun Capital, and Starry Capital continuing to increase their investment.Nurelit Healthcare was founded in 2016 by Mr. Qian Jihui, Mr. Li Maoliang, and Mr. Cai Jiming. The company focuses on research, development, and production.Medical Isotopes and RadiopharmaceuticalsAs the core business.

NuriLite HealthcareAn innovative nuclear medicine R&D pipeline comprising more than 10 products has been established. Among them,NRT6003 Injection isYttrium [⁹⁰Y] Carbon Microspheres Injection, is being carried out in China forPrimary Liver Cancer and Metastatic Liver CancerClinical research. The companyAnother radiopharmaceutical developed is NRT6008 Injection (AYttrium [⁹⁰Y] Charcoal Microspheres) has also been conducted in clinical research in China, targeting the indication of locally advanced unresectable cases.Pancreatic Cancer。

Stellar Vision Bio

Established: 2019

Financing Round:Pre-A+Round

News on March 19th, Xingmu Biotech announced the completion of a Pre-A+ round of financing worth tens of millions of RMB. This round was led byCairong VenturesLed by, with follow-up investments from Hefei Innovation Investment (Hefei High-Level Talent Project) and other institutions.Stellar Vision Bio was founded in 2019,Focusing on the development of ophthalmic gene therapy drugs, the companyFounder and CEO:Dr. Cai Yuan。Currently,The gene therapy class 1 innovative drug XMVA09 injection independently developed by StarEye Bio has previously been approved for clinical trials in China.Thisis a product that combinesAchieving Bispecific TargetingAndIntravitreal Injection CapsidGene therapy drugs,Intended for development in wAMD.

Huanuotai

Established: 2019

Financing Round: Series B

News on March 22: Huanuotai announced the completion of a 600 million yuan B-round financing. This round was jointly led by Beijing Medical and Health Industry Investment Fund and Mingtai Fund under Huayin Capital, with investments from Shuimu Chunjing Capital, Shunxi Fund under Beijing State Administration, Bencao Capital, and Jincheng Fund.Huanuotai was founded in 2019, dedicated to the research, development, and industrialization of human vaccines and innovative adjuvants. The company's founder and chairman is Mr. Hailong Wang.The funds from this Series B round will be mainly used by the companyHerpes zoster vaccine, influenza vaccine, and other productsThe advancement of clinical trials, as well as the construction of vaccine production bases and adjuvant production bases.

Hegia Bio

Established: 2021

Financing Round:A1Round

March 28), Hygieia Bio announced the completionNearly 100 Million Yuan in Series A1 Financing. This round of financing was led byTasly CapitalLed by [investor name], followed by Hedda Health and Shanghai Jianxin Capital, with existing shareholders continuing to increase their investment.Hedgia Bio was founded in 2021 and is committed to the construction of a delivery technology platform in the siRNA field and drug development.CEO isMr. Guan Tao.

Currently,Proviva Therapeutics' ProductsThe pipeline covers areas such as hepatitis B, non-alcoholic steatohepatitis (NASH), cardiovascular and metabolic diseases, complement-mediated related diseases, and neurological disorders.Among them, Kylo-0603 developed by the company is aDual-target Liver、GalNAc-Conjugated Small Molecule THR-β Agonist, Intended to develop treatment forModerate to Severe Fibrotic NASH. The companyCo-developed with Xingyao KunzeHT-101 is aNew siRNA drugs developed for chronic hepatitis B virus infection,Already approved for clinical use in China.

Zhiyi Biologic

Date of Establishment:2013Year

Financing Round:CWheel

On March 28, Zhiyi Bio announced the completion of a nearly 100 million RMBSeries C First Round Financing, this round byYuekexin FinancialLed by, with Aierui Investment following.Zhiyi Biotech was founded in 2013 and is dedicated to the research and development of live biotherapeutics.SK08, independently developed by Zhiyi Bio, is a live biotherapeutic product based on Bacteroides fragilis, which is currently under investigation for...IBS-D (Diarrhea-predominant Irritable Bowel Syndrome)Phase 3 clinical study.Another product developed by Zhiyi Biotechnology is SK10, which is aInactivated Bacteroides Fragilis, Intended for development to be used inChemotherapy-Induced Diarrhea (CID)。Previously,SK10The Phase 1 clinical trial in the United States has been completed.

Anlixi Rong

Established: 2017

Financing Round:CWheel

On March 28, Elixiron Immunotherapeutics announced that it had successfully completed a total ofNearly 100 million RMB equivalent in USD fund financing, this round of financing has received strong support from three US dollar funds.Anlixi Rong was founded in 2017 as a cutting-edge immunotherapy innovation technology company at the clinical stage.Founder and Chairman Dr. Chen Hongkai,The CEO is Ms. Duan Xiaohua.Currently, the company is committed to advancing key priorities.IFNγ Antibody Treatment for Vitiligo: Phase 1b/2 Clinical Development, andPhase 2 Clinical Study of CSF-1R-Targeted Small Molecule Drug EI-1071. According to EI-1071, the small molecule drug mainly targets improving neuroinflammation induced by microglial cells in the brain and is under development for the treatment ofAlzheimer's Disease。

Novobiom Biotech

Established: 2014

Financing Round: Pre-B+ Round

News on March 30, NEWISH announced that it has completedPre-B+ round financing worth tens of millions yuan led by Yicun CapitalNuo Wei Bio was founded in 2014 and is committed to the research and development of biologic innovative drugs in the anti-tumor field. The company's CEO is Dr. Liu Defang. Nuo Wei Bio has collaborated with Academician Jiang Jiandong to establish the nucleic acid drug development platform STARi.This platform adopts a strategy of targeting enhanced T-cell immunity by linking chemokines, aiming to develop a new generation of tumor vaccines.According to the news release from Novabio, the company has filed three Class 1 new drug applications and successfully obtained IND approvals in the past three years. The funds from this financing will mainly be used for its...Two Novel Class 1 Nucleic Acid-Based Tumor VaccinesClinical trial progress andNext-Generation Innovative Product PipelineDevelopment and registration submission.

In addition to the aforementioned companies, several other innovative drug companies also announced completed financing in March this year. Due to space limitations, this article will not introduce them one by one. It is hoped that, with the support of capital, these biopharmaceutical companies can accelerate the development progress of their candidate drugs and bring new treatment options to a wide range of patients as soon as possible.

Scan the QR code below, you will be able to access "Review of Global Financing Events Over $50 Million in March 2024》PDF file.

References:
[1] Official press releases from various companies

This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their WeChat Moments. Unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization, please leave a message on the "MedView" WeChat Official Account to contact us. For other cooperation inquiries, please contact wuxi_media@wuxiapptec.com.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Thirteen Chinese Innovative Biopharma Companies Secure New Funding Rounds

Proviva Therapeutics

▎WuXi AppTec Content Team Report

References:[1] Official press releases from various companies

References:
[1] Official press releases from various companies